PDCD1 and melanoma: For example, the anti-PD-1 antibody pembrolizumab has achieved objective responses in cancers as different as melanoma, lung cancer, head and neck, urothelial, gastric cancer, mesothelioma, and Hodgkin lymphoma, among others.